Leukaemia
Jul 26, 2022
VistaGen’s PH94B for Anxiety Disorder; Keytruda for Head and Neck Cancer Treatment; Bavarian Nordic’s Smallpox Vaccine Imvanex; CAMP4 Raises USD 100 Million; Incyte’s WU-CART-007; Incyte’s Opzelura for Vitiligo; AstraZeneca and Merck’s Lynparza; Sumitomo Pharma’s DSP-0390 for Brain Cancer
FDA Approves Incyte’s Opzelura as First Vitiligo Therapy The US Food and Drug Administration has approved Incyte’s Opzelura cream 1.5% for the topical treatment of non-segmental vitiligo in adult and paediatric patients 12 years of age and older. With this approval, Opzelura is the first and only FDA-approved...
Read More...
Jun 30, 2015
Chimeric Antigen Receptor T cell Therapy Market
“We designed CAR T cells to overcome a number of problems in getting T cells to attack Cancer”-says Eshhar, after the development of first CAR-T cells (1989). CAR-T Technologies and History of Innovations Ever so often in the history of immunotherapy, there comes a breakthrough that takes cancer research ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
